Review



soluble cd25 (scd25)  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    R&D Systems soluble cd25 (scd25)
    Treg numbers and suppressive function increased with CTLA4-Ig/IL-2 treatment throughout the 48-week treatment period. Changes in Treg suppressive function (A) , the percentage of CD4 + <t>CD25</t> + FOXP3 + cells (B) , the percentage of CD4 + CD25 + cells (C) , the percentage of CD4 + CD25 − cells (D) , and the percentage of CD8 + cells (E) throughout the study are shown. Changes in CD25 protein expression (F) and FOXP3 protein expression (G) in the CD4 + CD25 + FOXP3 + population by mean fluorescent intensity (MFI) throughout the study are shown. Data were analyzed by a one-way ANOVA with post-hoc Tukey test and p values less than 0.05 were considered significant. Data are expressed as mean ± SD. * p < 0.05, ** p < 0.01.
    Soluble Cd25 (Scd25), supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/soluble+cd25+%28scd25%29/pmc11195540-115-3-10?v=R%26D+Systems
    Average 90 stars, based on 1 article reviews
    soluble cd25 (scd25) - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "A phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic lateral sclerosis"

    Article Title: A phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic lateral sclerosis

    Journal: Frontiers in Neurology

    doi: 10.3389/fneur.2024.1415106

    Treg numbers and suppressive function increased with CTLA4-Ig/IL-2 treatment throughout the 48-week treatment period. Changes in Treg suppressive function (A) , the percentage of CD4 + CD25 + FOXP3 + cells (B) , the percentage of CD4 + CD25 + cells (C) , the percentage of CD4 + CD25 − cells (D) , and the percentage of CD8 + cells (E) throughout the study are shown. Changes in CD25 protein expression (F) and FOXP3 protein expression (G) in the CD4 + CD25 + FOXP3 + population by mean fluorescent intensity (MFI) throughout the study are shown. Data were analyzed by a one-way ANOVA with post-hoc Tukey test and p values less than 0.05 were considered significant. Data are expressed as mean ± SD. * p < 0.05, ** p < 0.01.
    Figure Legend Snippet: Treg numbers and suppressive function increased with CTLA4-Ig/IL-2 treatment throughout the 48-week treatment period. Changes in Treg suppressive function (A) , the percentage of CD4 + CD25 + FOXP3 + cells (B) , the percentage of CD4 + CD25 + cells (C) , the percentage of CD4 + CD25 − cells (D) , and the percentage of CD8 + cells (E) throughout the study are shown. Changes in CD25 protein expression (F) and FOXP3 protein expression (G) in the CD4 + CD25 + FOXP3 + population by mean fluorescent intensity (MFI) throughout the study are shown. Data were analyzed by a one-way ANOVA with post-hoc Tukey test and p values less than 0.05 were considered significant. Data are expressed as mean ± SD. * p < 0.05, ** p < 0.01.

    Techniques Used: Expressing



    Similar Products

    soluble cd25 (scd25)  (R&D Systems)
    90
    R&D Systems soluble cd25 (scd25)
    Treg numbers and suppressive function increased with CTLA4-Ig/IL-2 treatment throughout the 48-week treatment period. Changes in Treg suppressive function (A) , the percentage of CD4 + <t>CD25</t> + FOXP3 + cells (B) , the percentage of CD4 + CD25 + cells (C) , the percentage of CD4 + CD25 − cells (D) , and the percentage of CD8 + cells (E) throughout the study are shown. Changes in CD25 protein expression (F) and FOXP3 protein expression (G) in the CD4 + CD25 + FOXP3 + population by mean fluorescent intensity (MFI) throughout the study are shown. Data were analyzed by a one-way ANOVA with post-hoc Tukey test and p values less than 0.05 were considered significant. Data are expressed as mean ± SD. * p < 0.05, ** p < 0.01.
    Soluble Cd25 (Scd25), supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/soluble+cd25+%28scd25%29/pmc11195540-115-3-10?v=R%26D+Systems
    Average 90 stars, based on 1 article reviews
    soluble cd25 (scd25) - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    soluble cd25 (scd25  (R&D Systems)
    90
    R&D Systems soluble cd25 (scd25
    Treg numbers and suppressive function increased with CTLA4-Ig/IL-2 treatment throughout the 48-week treatment period. Changes in Treg suppressive function (A) , the percentage of CD4 + <t>CD25</t> + FOXP3 + cells (B) , the percentage of CD4 + CD25 + cells (C) , the percentage of CD4 + CD25 − cells (D) , and the percentage of CD8 + cells (E) throughout the study are shown. Changes in CD25 protein expression (F) and FOXP3 protein expression (G) in the CD4 + CD25 + FOXP3 + population by mean fluorescent intensity (MFI) throughout the study are shown. Data were analyzed by a one-way ANOVA with post-hoc Tukey test and p values less than 0.05 were considered significant. Data are expressed as mean ± SD. * p < 0.05, ** p < 0.01.
    Soluble Cd25 (Scd25, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/soluble+cd25+%28scd25%29/med_rxiv__2021__09__01__21262953-156-2-12?v=R%26D+Systems
    Average 90 stars, based on 1 article reviews
    soluble cd25 (scd25 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    soluble cd25 (scd25)  (Novo Nordisk)
    90
    Novo Nordisk soluble cd25 (scd25)
    Treg numbers and suppressive function increased with CTLA4-Ig/IL-2 treatment throughout the 48-week treatment period. Changes in Treg suppressive function (A) , the percentage of CD4 + <t>CD25</t> + FOXP3 + cells (B) , the percentage of CD4 + CD25 + cells (C) , the percentage of CD4 + CD25 − cells (D) , and the percentage of CD8 + cells (E) throughout the study are shown. Changes in CD25 protein expression (F) and FOXP3 protein expression (G) in the CD4 + CD25 + FOXP3 + population by mean fluorescent intensity (MFI) throughout the study are shown. Data were analyzed by a one-way ANOVA with post-hoc Tukey test and p values less than 0.05 were considered significant. Data are expressed as mean ± SD. * p < 0.05, ** p < 0.01.
    Soluble Cd25 (Scd25), supplied by Novo Nordisk, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/soluble+cd25+%28scd25%29/10__1158_slash_1078___0432__ccr___07___0410-179-4-16?v=Novo+Nordisk
    Average 90 stars, based on 1 article reviews
    soluble cd25 (scd25) - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    soluble cd25 (scd25  (Boehringer Mannheim)
    90
    Boehringer Mannheim soluble cd25 (scd25
    Synovial fluid parameters
    Soluble Cd25 (Scd25, supplied by Boehringer Mannheim, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/soluble+cd25+%28scd25%29/pmc01905611-104-18-21?v=Boehringer+Mannheim
    Average 90 stars, based on 1 article reviews
    soluble cd25 (scd25 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Treg numbers and suppressive function increased with CTLA4-Ig/IL-2 treatment throughout the 48-week treatment period. Changes in Treg suppressive function (A) , the percentage of CD4 + CD25 + FOXP3 + cells (B) , the percentage of CD4 + CD25 + cells (C) , the percentage of CD4 + CD25 − cells (D) , and the percentage of CD8 + cells (E) throughout the study are shown. Changes in CD25 protein expression (F) and FOXP3 protein expression (G) in the CD4 + CD25 + FOXP3 + population by mean fluorescent intensity (MFI) throughout the study are shown. Data were analyzed by a one-way ANOVA with post-hoc Tukey test and p values less than 0.05 were considered significant. Data are expressed as mean ± SD. * p < 0.05, ** p < 0.01.

    Journal: Frontiers in Neurology

    Article Title: A phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic lateral sclerosis

    doi: 10.3389/fneur.2024.1415106

    Figure Lengend Snippet: Treg numbers and suppressive function increased with CTLA4-Ig/IL-2 treatment throughout the 48-week treatment period. Changes in Treg suppressive function (A) , the percentage of CD4 + CD25 + FOXP3 + cells (B) , the percentage of CD4 + CD25 + cells (C) , the percentage of CD4 + CD25 − cells (D) , and the percentage of CD8 + cells (E) throughout the study are shown. Changes in CD25 protein expression (F) and FOXP3 protein expression (G) in the CD4 + CD25 + FOXP3 + population by mean fluorescent intensity (MFI) throughout the study are shown. Data were analyzed by a one-way ANOVA with post-hoc Tukey test and p values less than 0.05 were considered significant. Data are expressed as mean ± SD. * p < 0.05, ** p < 0.01.

    Article Snippet: Levels of soluble CD25 (sCD25) were also assayed by ELISA (R&D Systems, Cat# DR2A00) using sera from participants ( n = 4) and healthy controls ( n = 23) according to the manufacturer’s instructions.

    Techniques: Expressing

    Synovial fluid parameters

    Journal:

    Article Title: Increased synovial fluid levels of soluble CD23 are associated with an erosive status in rheumatoid arthritis (RA)

    doi: 10.1046/j.1365-2249.2000.01198.x

    Figure Lengend Snippet: Synovial fluid parameters

    Article Snippet: SF levels of sCD23, IL-1β, IL-3, IL-4, IL-6, IL-8, IL-10, IL-12 (Biosource Europe (formerly Medgenix), Fleurus, Belgium) and soluble CD25 (sCD25; Boehringer, Mannheim, Germany) were simultaneously determined by ELISA using specific MoAbs and according to the manufacturer’s recommendations.

    Techniques:

    Positive linear correlation between log soluble CD23 and log soluble CD25 in erosive knee−/hand+ RA (○) and erosive knee+/hand+ RA (•). r and P values are those obtained for the two groups studied together.

    Journal:

    Article Title: Increased synovial fluid levels of soluble CD23 are associated with an erosive status in rheumatoid arthritis (RA)

    doi: 10.1046/j.1365-2249.2000.01198.x

    Figure Lengend Snippet: Positive linear correlation between log soluble CD23 and log soluble CD25 in erosive knee−/hand+ RA (○) and erosive knee+/hand+ RA (•). r and P values are those obtained for the two groups studied together.

    Article Snippet: SF levels of sCD23, IL-1β, IL-3, IL-4, IL-6, IL-8, IL-10, IL-12 (Biosource Europe (formerly Medgenix), Fleurus, Belgium) and soluble CD25 (sCD25; Boehringer, Mannheim, Germany) were simultaneously determined by ELISA using specific MoAbs and according to the manufacturer’s recommendations.

    Techniques:

    Significant correlations for sCD23 and IL-10 in erosive rheumatoid arthritis

    Journal:

    Article Title: Increased synovial fluid levels of soluble CD23 are associated with an erosive status in rheumatoid arthritis (RA)

    doi: 10.1046/j.1365-2249.2000.01198.x

    Figure Lengend Snippet: Significant correlations for sCD23 and IL-10 in erosive rheumatoid arthritis

    Article Snippet: SF levels of sCD23, IL-1β, IL-3, IL-4, IL-6, IL-8, IL-10, IL-12 (Biosource Europe (formerly Medgenix), Fleurus, Belgium) and soluble CD25 (sCD25; Boehringer, Mannheim, Germany) were simultaneously determined by ELISA using specific MoAbs and according to the manufacturer’s recommendations.

    Techniques: